Sarepta Therapeutics’ Long-Term Potential Is in Flux

1 min read

Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). But the biotech’s valuation is still largely based on its potential to treat a large portion of DMD patients with its gene therapy SRP-9001. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss Sarepta’s fourth-quarter results and why investors should still be focused on the company’s pipeline.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Fortinet Partners With Linksys to Secure Work-From-Home Employees

Next Story

3 Reasons Adobe Stock Is a Reopening Play

Latest from Blog